Letrozol Pensa Pharma

Letrozole, the active ingredient in Letrozol Pensa Pharma, is an aromatase inhibitor presented as an oral tablet for systemic use. It is employed in the treatment of postmenopausal estrogen receptor‑positive breast cancer, where it reduces estrogen production to inhibit tumor growth.

GNH USA supplies Letrozol Pensa Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Letrozole is indicated for hormone‑dependent breast cancer and works by targeting estrogen synthesis. - Postmenopausal estrogen receptor‑positive breast cancer: reduces tumor progression by lowering circulating estrogen levels. - Adjuvant therapy for early‑stage hormone‑receptor positive breast cancer: decreases risk of recurrence after surgery. - Metastatic hormone‑receptor positive breast cancer in postmenopausal women: helps control disease spread by suppressing estrogen‑driven growth.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Osteoporosis: decreased bone mineral density leading to fractures. - Cardiovascular events: increased risk of thromboembolic disease. - Severe liver injury: marked elevation of hepatic enzymes or hepatitis.

When prescribing Letrozole, clinicians should consider several safety measures and monitoring requirements. - Bone health monitoring: assess bone mineral density regularly and consider calcium/vitamin D supplementation. - Cardiovascular assessment: evaluate risk factors for thromboembolism before initiation. - Liver function testing: perform baseline and periodic liver enzyme tests. - Drug interactions: review concomitant medications for potential CYP2A6 inhibitors or inducers. - Store at ambient temperature: keep tablets below 25 °C in the original container, protect from moisture and light.

Letrozole can interact with other medicines that affect its metabolism or hormonal pathways.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors (e.g., fluvoxamine): may increase Letrozole plasma levels, raising toxicity risk. - Estrogen‑containing hormonal therapies (e.g., hormone replacement therapy): counteract Letrozole’s estrogen‑lowering effect.

Moderate Interactions (Monitor Closely): - CYP2A6 inducers (e.g., rifampicin): may reduce Letrozole exposure, diminishing efficacy. - Anticoagulants (e.g., warfarin): Letrozole may enhance anticoagulant effect, requiring INR monitoring. - Tamoxifen: concurrent use may increase risk of adverse events; clinical judgment required.